ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 949

Long-Term Rheumatic and Musculoskeletal Disorders Associated to Ebola Virus Infection

Yves-Marie PERS1,2, Anne DUBOIS3, Alimou BARRY4, Mariama SALL4, Mamadou SALIOU SOW5, Bernard TAVERNE6, Laura MARCH6, Jean-François ETARD6, Moumié BARRY7, Abdoulaye TOURE8 and Eric DELAPORTE6, 1Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital Montpellier, MONTPELLIER, France, 2INSERM U1183, IRMB, INSERM U1183, Montpellier, France, 3Clinical immunology and osteoarticular diseases Therapeutic Unit, Lapeyronie University Hospital, Montpellier, France., Montpellier, France, 4Infectious disease, Donka University National Hospital, Conakry, Guinea, 5Infectious Disease, Donka University National Hospital, CONAKRY, Guinea, 6IRD UMI 233 INSERM U1175, University Montpellier, MONTPELLIER, France, 7Hôpital National Donka, CHU de Conakry, Service des Maladies Infectieuses et Tropicales, Conakry, Guinea, 8Department of Pharmacy, Conakry University, CONAKRY, Guinea

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: complications and musculoskeletal disorders, Ebola virus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S104 ACR Abstract: Infection-Related Rheumatic Disease (946–951)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Between December 2013 and April 2016, the largest epidemic of Ebola virus disease (EVD) to date generated more than 28,000 cases and more than 11,000 deaths in the large, mobile populations of Guinea, Liberia, and Sierra Leone. However, based on the small size of past outbreaks in remote and resource-poor locations that hinder systematic study, there is little knowledge of the frequency of various sequelae post-EVD, their pathogenesis, and optimum treatment. Some short-term and long-term health problems have been reported such as arthralgia and/or maylagia1.

Methods: The Postebogui study is a prospective multicenter cohort aiming to evaluate the long-term clinical, psychological and socio-behavioral outcomes of EVD survivors infected during the 2014-2015 outbreaks2. Nearly 80% of survivors in Guinea were included in the Postebogui cohort. We organized the systematic rheumatic screening of all patients included in the Postebogui cohort (Conakry) regardless of the disease status. A musculoskeletal (MS) Doppler ultrasound (DUS) assessment was performed (Esaote MyLab). Data were collected using a standardized questionnaire and entered into an electronic database.

Results:

Of the 382 participants included in the Postebogui cohort in Conakry, 313 patients underwent a complete interview by a rheumatologist nearly 3-year after viral infection: 36 patients never presented joint or muscle pain, 61 patients had experienced previous pain and 216 patients still reported chronic MS pain (69%). No demographic differences were found between both groups except that children significantly reported less chronic MS pain.

In the painful group, 58% were female; median age was 29.1 years; median time from Ebola Treatment Center (ETC) discharge to rheumatologic examination was 36 months. Pain manifestations started before EVD for 41 patients (19%). Morning stiffness was present in 46% of patients. Patients had mechanical pain (48%), inflammatory pain (18%) or both (34%). Axial and peripheral were largely involved (84%). Large joints were most frequently affected (89%). Polyarticular presentations were predominant with a symmetrical pain distribution. Furthermore, 91% had at least one painful enthesitis. DUS showed 5 patients with tenosynovitis and 4 patients with synovitis but without hyperemia. One patient suffered with Pes anserine tendonitis. Diagnoses were mainly non-specific MS disorders (67%) and low back pain (39%). No rheumatoid arthritis was retained but axial spondyloarthritis with enthesitis was suspected in few cases (2%).

Conclusion: Our study provides the largest accurate description of MS disorders in the Post-Ebola syndrome with a long-term follow-up (3 year after Ebola infection). Rheumatic sequelae are frequent and pathophysiological mechanisms need to be explored in the future.

References

1Pers YM et al. Rheumatology 2017

2Etard JF et al. Lancet Infectious Diseases 2017


Disclosure: Y. M. PERS, None; A. DUBOIS, None; A. BARRY, None; M. SALL, None; M. SALIOU SOW, None; B. TAVERNE, None; L. MARCH, None; J. F. ETARD, None; M. BARRY, None; A. TOURE, None; E. DELAPORTE, None.

To cite this abstract in AMA style:

PERS YM, DUBOIS A, BARRY A, SALL M, SALIOU SOW M, TAVERNE B, MARCH L, ETARD JF, BARRY M, TOURE A, DELAPORTE E. Long-Term Rheumatic and Musculoskeletal Disorders Associated to Ebola Virus Infection [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/long-term-rheumatic-and-musculoskeletal-disorders-associated-to-ebola-virus-infection/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-rheumatic-and-musculoskeletal-disorders-associated-to-ebola-virus-infection/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology